Background: Naringenin, a natural resource-derived flavanone, exhibits a plethora of pharmacological properties. The present study aimed to investigate the effects of Naringenin on obesity-associated hypertension and its underlying mechanism.
Methods: Obesity-associated hypertension rat model was established with a high-fat diet (HFD) and was administrated with Naringenin (25, 50, 100 mg/kg). Body and fat weight were recorded and blood pressure was measured. Serum lipid parameters (cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides), oxidative stress biomarkers (malondialdehyde (MDA), superoxide dismutase (SOD), nitrite oxide (NO), and glutathione (GSH)), and adipocytokines (leptin and adiponectin) were determined. The expressions of signal transducer and activator of transcription (STAT) 3 were determined by using Western blotting.
Results: Treatment with Naringenin (100 mg/kg) reduced body and fat weight in HFD-induced rats. Besides, treatment with Naringenin (50 and 100 mg/kg) reduced blood pressure and regulated lipid parameters by decreasing cholesterol, triglycerides, and LDL and increasing HDL. Treatment with Naringenin (50 and 100 mg/kg) reduced serum MDA and NO, whereas increased serum SOD and GSH. Furthermore, Treatment with Naringenin (50 and 100 mg/kg) regulated adipocytokines and decreased the phosphorylation of STAT3.
Conclusion: Naringenin ameliorates obesity-associated hypertension by regulating lipid disorder and oxidative stress.